41 related articles for article (PubMed ID: 38584451)
1. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms involved in the pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype.
Fiocca R; Luinetti O; Villani L; Mastracci L; Quilici P; Grillo F; Ranzani GN
Hepatogastroenterology; 2001; 48(42):1523-30. PubMed ID: 11813565
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
[TBL] [Abstract][Full Text] [Related]
4. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
5. Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis.
Mingchao ; Devereux TR; Stockton P; Sun K; Sills RC; Clayton N; Portier M; Flake G
Exp Toxicol Pathol; 2001 Sep; 53(4):237-46. PubMed ID: 11665847
[TBL] [Abstract][Full Text] [Related]
6. Three independent genetic profiles based on mucin expression in early differentiated-type gastric cancers--a new concept of genetic carcinogenesis of early differentiated-type adenocarcinomas.
Sugai T; Habano W; Uesugi N; Jao YF; Nakamura S; Abe K; Takagane A; Terashima M
Mod Pathol; 2004 Oct; 17(10):1223-34. PubMed ID: 15154009
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type.
Ranzani GN; Luinetti O; Padovan LS; Calistri D; Renault B; Burrel M; Amadori D; Fiocca R; Solcia E
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):223-31. PubMed ID: 7606196
[TBL] [Abstract][Full Text] [Related]
8. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
9. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
10. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
Hashimoto T; Ogawa R; Tang TY; Yoshida H; Taniguchi H; Katai H; Oda I; Sekine S
Mod Pathol; 2019 Apr; 32(4):568-575. PubMed ID: 30425335
[TBL] [Abstract][Full Text] [Related]
11. Distinct expression profile of key molecules in crawling-type early gastric carcinoma.
Woo HY; Bae YS; Kim JH; Lee SK; Lee YC; Cheong JH; Noh SH; Kim H
Gastric Cancer; 2017 Jul; 20(4):612-619. PubMed ID: 27734272
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive mutation profiling of mucinous gastric carcinoma.
Rokutan H; Hosoda F; Hama N; Nakamura H; Totoki Y; Furukawa E; Arakawa E; Ohashi S; Urushidate T; Satoh H; Shimizu H; Igarashi K; Yachida S; Katai H; Taniguchi H; Fukayama M; Shibata T
J Pathol; 2016 Oct; 240(2):137-48. PubMed ID: 27313181
[TBL] [Abstract][Full Text] [Related]
13. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
